By Ian Walker

AstraZeneca PLC (AZN) said Thursday that Calquence met two of its goals in the latest trial for previously untreated chronic lymphocytic leukaemia.

The pharmaceutical giant said that Calquence, in combination with obinutuzumab, demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival compared with the chemotherapy-based combination of chlorambucil and obinutuzumab.

It also showed a statistically significant and clinically meaningful improvement in progression-free survival compared to the chemotherapy and obinutuzumab regimen.

"This is the second Calquence pivotal trial in CLL [chronic lymphocytic leukaemia] to meet its primary endpoint early, following the positive results of the ASCEND trial, announced in May," AstraZeneca said.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

June 06, 2019 02:36 ET (06:36 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.